Monika Kmeťová Sivoňova1, Marta Pisková1, Dušan Dobrota1, Róbert Dušenka1,2, Svetlana Grobarčíková2, Silvia Mahmood1, Ján Kliment2
Introduction and Aims: The N-acetyltransferase 2 (NAT2) enzyme detoxifies a wide spectrum of naturally occurring xenobiotics including carcinogens and drugs. Variation at the NAT2 gene has been linked to the human acetylation capacity, either “slow” or “fast”, which modifies susceptibility to cancer and adverse drug reactions. The aim of our pilot study was to investigate whether NAT2 genotypes/phenotypes are associated with increased risk factor for prostate cancer in the Slovak population and to study the clinico-pathological correlations and the prognostic significance of NAT2. Material and Methods: We genotyped four common single nucleotide polymorphisms (SNPs) in NAT2 among 179 prostate cancer patients and 269 healthy controls by using PCR-RFLP (polymerase chain reaction restriction fragment length polymorphism analysis). Relative risk of prostate cancer for NAT2 genotypes/NAT2 acetylation phenotypes was estimated using chi squared method. Results: We observed no significant association between NAT2 genotypes/phenotypes and prostate cancer risk. We have found that rapid acetylators have significantly higher serum PSA levels than slow acetylators (p < 0.05), indicating increase generation of carcinogens and enhance tumourogenesis. Conclusions: Data of our pilot study demonstrate that the NAT2 polymorphism is not associated with the risk of developing prostate cancer in the Slovak population. Future studies concerning the association of NAT2 genotypes and environmental/lifestyle factors will be important to elucidate the real meaning of NAT2 polymorphisms in the susceptibility to prostate cancer.